These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 25600908

  • 1. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
    Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P.
    Biochem Pharmacol; 2015 Mar 15; 94(2):79-90. PubMed ID: 25600908
    [Abstract] [Full Text] [Related]

  • 2. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
    Beretta GL, Alampi D, Corno C, Carenini N, Corna E, Perego P.
    Int J Mol Sci; 2024 May 06; 25(9):. PubMed ID: 38732265
    [Abstract] [Full Text] [Related]

  • 3. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G, Gekeler V, Leja A, Beckers T, Boehm M.
    Cancer Res; 2006 May 15; 66(10):5409-18. PubMed ID: 16707469
    [Abstract] [Full Text] [Related]

  • 4. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, Gonzalez-Barón M, Perona R.
    Oncogene; 2006 Jun 01; 25(23):3335-45. PubMed ID: 16462770
    [Abstract] [Full Text] [Related]

  • 5. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS, Lee SC, Min HY, Park KH, Hyun SY, Kwon SJ, Choi SP, Kim WY, Lee HJ, Lee HY.
    Cancer Lett; 2015 Jun 01; 361(2):197-206. PubMed ID: 25721083
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K.
    Lung Cancer; 2013 Nov 01; 82(2):214-21. PubMed ID: 24051085
    [Abstract] [Full Text] [Related]

  • 8. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
    Sun Y, Bao X, Ren Y, Jia L, Zou S, Han J, Zhao M, Han M, Li H, Hua Q, Fang Y, Yang J, Wu C, Chen G, Wang L.
    Cell Death Dis; 2019 May 24; 10(6):400. PubMed ID: 31127087
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J.
    Cancer Chemother Pharmacol; 2006 Dec 24; 58(6):776-84. PubMed ID: 16532342
    [Abstract] [Full Text] [Related]

  • 14. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
    Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F.
    Clin Cancer Res; 2010 Aug 01; 16(15):3944-53. PubMed ID: 20562210
    [Abstract] [Full Text] [Related]

  • 15. Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
    To KKW, Cheung KM, Cho WCS.
    J Cancer Res Clin Oncol; 2023 Aug 01; 149(10):7217-7234. PubMed ID: 36905422
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)].
    Brabec V, Griffith DM, Kisova A, Kostrhunova H, Zerzankova L, Marmion CJ, Kasparkova J.
    Mol Pharm; 2012 Jul 02; 9(7):1990-9. PubMed ID: 22591133
    [Abstract] [Full Text] [Related]

  • 20. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S, Sankar R, Varunkumar K, Ravikumar V.
    Biomed Pharmacother; 2014 Apr 02; 68(3):327-34. PubMed ID: 24485799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.